Reading Room

Hot Topics in Workers' Compensation 2009 Seminar

Jon 15249

This seminar will provide practitioners with new strategies and techniques to handle workers' compensation cases in the changing economy.This fast-paced program features a panel of some of the most respected New Jersey Workers' Compensation Judges and attorneys, who will review and provide insight on the top issues and cases that have emerged during the past year.

FDA Alerts Consumers Concering Zicam®

Jon 8074

Jon L. Gelman LLC is investigating cases involving individuals who have suffered the loss of taste and smell (anosmia) after using Zicam®. Zicam® is an over-the-counter nasal spray used to relieve the symptoms associated with the common cold and flu and is manufactured by Matrixx Initiatives. Matrixx manufactures a range of products under the Zicam® name, but the name Zicam® is generally used to refer to its over-the-counter nasal zinc solution spray.  

St. Paul Travelers Announces $90 Million Settlement of Common Law Asbestos-Related Direct Actions

Jon 8738

The St. Paul Travelers Companies, Inc. announced that it has executed an agreement resolving substantially all common law asbestos-related direct actions pending against its Travelers Property Casualty Corp. subsidiaries ("Travelers"). These actions allege, among other things, a general, non-statutory duty to disclose to the public the hazards of asbestos. The settlement, if it receives court approval, would also bar similar future direct actions against Travelers. 

Hispanic Workers Have High Death Rates

Jon 6340

The Centers for Disease Control (CDC) has again reported higher death dates for Hispanic workers in the United States. Hispanic workers are one of the fastest growing segments in the US workforce and their death rate has been reported as consistently high.

Pittsburg Corning Plans to Pay Asbestos Victims $825 Million

Jon 9988

PPG Industries (Pittsburg Corning Corp.) and its insurers plan to pay out millions of dollars to victims of asbestos disease. In a bankruptcy reorganization plan filed with the Court for its approval, it was announced that PPG intended to pay out $825 Million in cash over the next 15 years.

Raptiva® Withdrawn From Market for High Risk of Fatal Brain Disease

Jon 6784

We are investigating cases in which Raptiva® users have experienced neurological changes including unusual weakness, loss of coordination and changes in vision.

On April 8, 2009, the drug manufacturer Genentech announced a phased withdrawal of the psoriasis drug Raptiva® (efalizumab) from the U.S. market.
 

First2345791011Last

CONTACT US
1.973.696.7900
jon.gelman@gmail.com